Failure of manufacturers to report adverse events may result in...

• A. Delayed risk assessment
• B. Increased manufacturing efficiency
• C. Enhanced product safety
• D. Immediate regulatory approval

Answer: (A)

Adverse event reporting is a key part of pharmacovigilance and post-market surveillance. When manufacturers fail to report adverse events, the data needed to evaluate the true safety profile of a product are incomplete or delayed. Regulators and manufacturers rely on timely reports to detect safety signals, assess the overall risk-benefit balance, and decide whether actions such as label changes, warnings, or recalls are needed. Without these timely reports, the risk assessment cannot be conducted promptly, leading to delays in understanding and mitigating potential risks.

The other options don’t fit because failure to report adverse events does not improve manufacturing efficiency, does not enhance product safety (safety depends on identifying and managing risks, which requires reporting), and does not lead to immediate regulatory approval (regulators require complete safety data and may delay approval if adverse events are under-reported).